NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Accretive Health

(AH)

was downgraded to Sell at TheStreet Ratings.

Dolby

(DLB) - Get Report

was downgraded at JP Morgan from Overweight to Neutral. Company lacks near-term catalysts, JP Morgan said. $48 price target.

Extra Space Storage

(EXR) - Get Report

was downgraded at Jefferies to Hold from Buy. Valuation hard to ignore, Jefferies said.

General Growth

(GGP)

was upgraded at UBS to Buy from Neutral. $20 price target. Estimates were also increased on multiple near-term catalysts, UBS said.

Human Genome

( HGSI) was downgraded at Leerink Swann to Market Perform. See little upside potential to Glaxo's hostile bid, Leerink Swann said.

Highwood Properties

(HIW) - Get Report

was downgraded at Jefferies to Hold from Buy. $36 price target. Valuation now reflects fundamentals, Jefferies said.

Harsco

(HSC) - Get Report

was upgraded at Keybanc from Hold to Buy. $27 price target. Management change should improve shareholder value, Keybanc said.

Martin Marietta

(MLM) - Get Report

was downgraded at RBC Capital to Sector Perform. Valuation call, based on a $99 price target, RBC Capital said.

3M

(MMM) - Get Report

was downgraded at Bernstein from Outperform to Market Perform. $101 price target. Company is trying to balance between growth and margins, Bernstein said.

Vail Resorts

(MTN) - Get Report

was downgraded at Wells Fargo from Outperform to Market Perform. Company lacks near-term catalysts, Wells Fargo said.

Oracle

(ORCL) - Get Report

was downgraded at ThinkEquity from Buy to Hold. $28 price target. New analyst believes that the company lacks near-term catalysts, ThinkEquity said.

Pros Holdings

(PRO) - Get Report

was downgraded to Hold at TheStreet Ratings.

Prudential

(PRU) - Get Report

was upgraded at Credit Suisse from Equal-Weight to Overweight. Valuation call, based on a $66 price target, Credit Suisse said.

Teva Pharmaceutical

(TEVA) - Get Report

was downgraded at Needham from Strong Buy to Hold. Company is posting lower sales and withdrew its guidance, Needham said.

Marriott Vacations

(VAC) - Get Report

was upgraded at Goldman Sachs from Neutral to Buy. Valuation call, based on a $38 price target, Goldman Sachs said.

STOCK COMMENTS / EPS CHANGES

BMC Software

(BMC)

price target was raised at Jefferies to $48. Operational improvements place company in a better position, Jefferies said.

Cisco

(CSCO) - Get Report

estimates, price target were reduced at FBR Capital Markets. Shares are now seen reaching $20. Estimates were also cut, given the company's new guidance, FBR said. Market Perform rating.

Cisco Systems numbers were lowered at Oppenheimer. Shares are now seen reaching $22. Estimates were also lowered on guidance below consensus, Oppenheimer said. Outperform rating.

Commvault

(CVLT) - Get Report

estimates, price target were raised at Credit Suisse. Shares are now seen reaching $50. Estimates were also increased, as Simpana is driving growth, Credit Suisse said. Neutral rating.

Dean Foods

(DF) - Get Report

numbers were raised at Credit Suisse. Shares are now seen reaching $16. Estimates were also increased, given better business momentum, Credit Suisse said. Neutral rating.

Ingersoll-Rand

(IR) - Get Report

price target was boosted at Bank of America/Merrill Lynch to $50. Activist investor could help unlock shareholder value, BofA/Merrill said.

Priceline.com

(PCLN)

estimates were increased at Benchmark through 2013. Bookings growth remains strong, Benchmark said. Buy rating and $840 price target.

Rosetta Resources

(ROSE) - Get Report

numbers were lowered at Credit Suisse. Estimates were cut through 2014. Company is seeing slower production growth and lower prices, Credit Suisse said. Outperform rating and new $70 price target.

Spectrum Brands

(SPB) - Get Report

numbers were increased at Credit Suisse. Estimates were boosted through 2013. Company is seeing higher sales and cutting costs, Credit Suisse said. Outperform rating and new $40 price target.

Teva Pharmaceutical estimates were cut at Morgan Stanley through 2014. Company is facing higher generic competition and has limited pipeline visibility, Morgan Stanley said. Equal-Weight rating and new $47 price target.

>To submit a news tip, email:

tips@thestreet.com

.

READERS ALSO LIKE:

>>3 Hot Stocks for a Sideways Market

>>Prudential Financial Gets Two Upgrades

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

This article was written by a staff member of TheStreet.